The title of my presentation 'ABPM: a criticism' means that it will concern some of the themes that have been debated about ambulatory blood pressure (ABP) during the last 20 years.
Normal values of ambulatory pressure
The first point that I want to stress is about the socalled normality of monitored BP: a topic which has attracted the attention of many researchers, among whom here in Italy include Prof. Mancia's group 1 and Palatini and Pessina 2 from our group in Padova. Discussing this topic means that ABP values may differ from those of conventionally measured blood pressure. But, before starting my considerations on this point, let me remember what we mean when speaking of a 'normal BP'. The concept of normality, for blood pressure as for any of the so-called risk factors, is indeed a pure abstraction since the 'risk' is increasing continuously from the lowest to the highest values of each factor. Moreover, we know very well that BP values are distributed in any population in such a way as to realise an unimodal curve, like those taken from our survey on more than 15 000 inhabitants in the Veneto Region. 3 Looking at these as to many other distribution curves in populations, it is quite impossible to find some point where to put the threshold separating normality from hypertension. It is for this reason that the threshold point has been displaced many times over the years, and that Geoffrey Rose could ironically say that it is that value over which treatment is more beneficial than harmful.
After these obvious but necessary premises let us consider the problem of the normality of ABP based on the differences between 'clinic' or 'conventional' and monitored BP. Doing this analysis I will take in account only the daytime values of monitored BP, because 'clinic' BP is never measured during the night hours.
All researchers convene that the mean daytime monitored BP is somehow lower than the 'clinic' one. However, doing this comparison, we encounter some evident bias. First of all, the difference between the two values is not constant in all subjects but is largely variable: moreover, even if 'clinic' BP is usually somehow higher than the monitored one, in some cases it may be equal or even lower.
This means that we can standardise the mean difference between clinic and monitored BP, as Palatini et al in our group 4 have tried to do in a large group of patients, but in the single case we have no possibility of predicting which is the real difference between 'his' clinic and 'his' monitored BP.
A second bias is due to the fact that while the measurement of 'clinic' BP is standardised-at least in clinical surveys-that of ABP is not: the patient's daytime during enregistration may be characterised by some enjoyable and quiet activities, or on the contrary be physically tiring or spent dealing with unpleasant stimuli. Clearly, the profile of the daytime curve and its mean value will be directly affected by this different setting, as Palatini et al 5 have clearly demonstrated, by enregistering three curves for the same subject on different days.
A third point concerns the common observation that if we measure the 'clinic' BP in a group of individuals repeatedly over weeks or months the distribution curves of their BP values will vary, because BP tends to regress toward the mean, with a prevalent reduction of the highest BP values: this has been well demonstrated by our groups' experience in the context of a pilot study of WHO co-ordinated by Tom Strasser in the 1970s. 6 Later observations have confirmed this observation (MRC study, 7 Australian study 8 ). We do not yet know if the same will happen when monitoring BP in the same circumstances, however we know that by repeating BP monitoring in the same subjects both the shape of the curves and the mean values of BP can vary significantly. As a consequence, a single ambulatory monitored BP cannot be considered as a 'Gold Standard' for comparison with any 'clinic' BP measurement.
A final observation is that the difference between 'clinic' and daytime monitored BP depends on the level of clinic BP. In our group, Palatini et al 4 have clearly demonstrated that the difference is minimal when 'clinic' BP is normal or borderline but it becomes quite high in hypertensive patients.
Summing up we may say: (a) that a 'normal' BP does not exist; (b) that since we cannot state a constant value for the difference between 'clinic' and monitored BP, it is impossible to predict, in a single subject, which will be the level of the BP measured with different methods; (c) that monitored BP cannot be considered as a Gold Standard for any clinical evaluation.
ABPM and the diagnosis of hypertension
Only a few words on the utility of ABPM for diagnosing hypertension.
Usually we do not need ambulatory monitoring for diagnostic purposes, being largely sufficient using the simpler conventional method: a subject is hypertensive if his casual BP is higher than 140/90 mm Hg.
We do not yet know the real meaning of finding a monitored BP higher than the clinic one, because we do not know if in these cases clinic BP will be increasing over time or if monitored BP will return towards lower ('normal') values. We hope that the Harvest Study, which is in progress in Padua, 9 will clear this interesting point in the near future.
For diagnostic purposes, ABPM will be extremely useful in those few cases in which 'clinic' BP results are constantly high, despite a good antihypertensive treatment and/or in the absence of any organ complications, mainly left ventricular hypertrophy. In such cases ABPM may reveal that the mean daytime BP is effectively much lower than it appears by clinic measurement and that the high values found with the conventional method are due to a persistent 'white coat' effect.
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ABPM and prognosis
For prognostic purposes the 24-h mean BP should theoretically be the best indicator, since it tells us what is the mean haemodynamic stress on the arterial walls during the whole day. Many observations have been reported in the literature confirming this hypothesis. 11, 12 Unfortunately, even in the future, we will never be able to collect such a mass of data with ABPM as those which have been gathered by those large prospective trials which have been permitted to McMahon to trace his well known metanalitic curves. This impossibility is both due to the complexity of the methodology and to the difficulty of finding, at the present time, a sufficiently large cohort of hypertensives not yet treated with antihypertensive drugs. For this reason we still have to rely on 'clinic' BP for any prognostic evaluation.
ABPM and antihypertensive treatment
My last considerations concerns the usefulness of ABPM in the pharmacological treatment of high BP.
No doubt that ABPM is the most suitable method for monitoring the effects of any antihypertensive drug during 24 or 48 h of observation. It will tell us the 'peak' and 'trough' effect of the drug, its efficacy on reducing the variability of BP, its effect during the night hours and at the waking time, and so on. [13] [14] [15] On the contrary, ABPM is not equally useful for long term monitoring of anthypertensive treatment, for which self measured (or home measured) BP may be considered the methodology of choice.
As Mancia et al 1 have demonstrated, home BP values are not much different from those of mean 24-h monitored BP. The measurement is easily performed at home by the patient or by some of his relatives, both with conventional or automatic devices, it is costless and not so time-consuming as ABPM.
For all these reasons, home BP measurement has been emphatically recommended by the World Hypertension League. 16 Concluding this short survey on ABPM, I want to stress once again that: (a) one of the most futile arguments which has been raised in recent years is the search for a 'normal' value of monitored BP; (b) ABPM may be useful for diagnosing hypertension only in a few, very selected cases; (c) for prognostic purposes ABPM cannot be utilised, due to the lack of information that we have and for the practical impossibility of gathering data from sufficiently large cohorts of non-treated hypertensives; (d) ABPM may be substituted by home BP measurement for a long-term follow-up of hypertensive patients during pharmacological treatment; (e) ABPM is instead very useful-as has been repeatedly saidfor other purposes, mainly in research and for the short-term evaluation of antihypertensive drugs.
In conclusion, we must remember that ABPM is a costly and time-consuming method and that its utilisation in clinical practice has not to be overemphasised.
